Shares of Lupin soared 3 per cent on the Bombay Stock Exchange after the drug maker received final approval from the US FDA to market generic Nadolol tablets in the American market.
Buoyed by the development, shares of the company gained as much as 2.99 per cent to trade at intra-day high of Rs 1,070.95 apiece on the Bombay Stock Exchange.
In a similar fashion, shares of the company were trading 2.34 per cent higher at Rs 1,064.30 apiece on the National Stock Exchange.
Meanwhile, the broader benchmark BSE Sensex was trading at 31,946.19, up 99.30 points, or 0.31 per cent, at 11:50 hours.